Literature DB >> 21814224

p53 Arg72Pro and MDM2 309 SNPs in hereditary retinoblastoma.

Maria Carmela Epistolato1, Vittoria Disciglio, Gabriella Livide, Paola Berchialla, Maria Antonietta Mencarelli, Annabella Marozza, Mariangela Amenduni, Theodora Hadjistilianou, Sonia De Francesco, Antonio Acquaviva, Paolo Toti, Francesco Cetta, Francesca Ariani, Mario De Marchi, Alessandra Renieri, Daniela Giachino.   

Abstract

The tumor suppressor p53 and its negative regulator MDM2 have crucial roles in a variety of cellular functions such as the control of the cell cycle, senescence, genome stability and apoptosis, and are frequently deregulated in carcinogenesis. Previous studies have highlighted the contribution of the common functional polymorphisms p53 p.Arg72Pro and MDM2 309SNP to the risk of both common cancers and Li-Fraumeni syndrome. Their possible role in retinoblastoma has recently been addressed by Castéra et al, who however only studied the MDM2 309SNP. Here, for the first time, we analyzed both single nucleotide polymorphisms (SNPs) in a case-control study of 111 Italian hereditary retinoblastoma patients. We found a significant association of the p53 Pro/Pro genotype with the disease (odds ratio=3.58, P=0.002). The MDM2 309SNP showed a weak negative association of allele G that deserves further investigation. These findings further support the hypothesis that genetic variability of the p53 pathway contributes to the individual susceptibility to retinoblastoma, as shown for Li-Fraumeni syndrome and a variety of non-hereditary cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21814224     DOI: 10.1038/jhg.2011.82

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  8 in total

Review 1.  The genomic landscape of retinoblastoma: a review.

Authors:  Brigitte L Thériault; Helen Dimaras; Brenda L Gallie; Timothy W Corson
Journal:  Clin Exp Ophthalmol       Date:  2013-05-22       Impact factor: 4.207

2.  Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.

Authors:  Francesca Ponti; Serena Corsini; Maria Gnoli; Elena Pedrini; Marina Mordenti; Luca Sangiorgi
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

Review 3.  Biomarkers in retinoblastoma.

Authors:  Jie Sun; Hui-Yu Xi; Qing Shao; Qing-Huai Liu
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

4.  Association between MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270 polymorphisms and retinoblastoma susceptibility.

Authors:  Qixin Cao; Yun Wang; Xiaohui Song; Weihua Yang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

5.  The mouse double minute 2 309T>G polymorphism and retinoblastoma risk: A meta-analysis.

Authors:  K Sooraj; Sunil Kumar; Amit Kumar; Mandeep S Bajaj; Jasbir Kaur
Journal:  Saudi J Ophthalmol       Date:  2021-02-27

6.  Association of p53 rs1042522, MDM2 rs2279744, and p21 rs1801270 polymorphisms with retinoblastoma risk and invasion in a Chinese population.

Authors:  Rongxin Chen; Shu Liu; Huijing Ye; Jiali Li; Yi Du; Lingyan Chen; Xiaoman Liu; Yungang Ding; Qian Li; Yuxiang Mao; Siming Ai; Ping Zhang; Wenfang Ma; Huasheng Yang
Journal:  Sci Rep       Date:  2015-08-20       Impact factor: 4.379

7.  A Functional Polymorphism (rs937283) in the MDM2 Promoter Region is Associated with Poor Prognosis of Retinoblastoma in Chinese Han Population.

Authors:  Yongfa Jiao; Zhongming Jiang; Yuxia Wu; Xiaochong Chen; Xing Xiao; Haiying Yu
Journal:  Sci Rep       Date:  2016-08-10       Impact factor: 4.379

Review 8.  Genetic Predisposition to Solid Pediatric Cancers.

Authors:  Mario Capasso; Annalaura Montella; Matilde Tirelli; Teresa Maiorino; Sueva Cantalupo; Achille Iolascon
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.